These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 24065233)
1. Diagnostic accuracy of Cyfra 21-1 for head and neck squamous cell carcinoma: a meta-analysis. Wang YX; Hu D; Yan X Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2383-9. PubMed ID: 24065233 [TBL] [Abstract][Full Text] [Related]
2. A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Yen TC; Lin WY; Kao CH; Cheng KY; Wang SJ Clin Otolaryngol Allied Sci; 1998 Feb; 23(1):82-6. PubMed ID: 9563673 [TBL] [Abstract][Full Text] [Related]
3. CYFRA 21-1: a suitable tumor marker in patients with head and neck cutaneous squamous cell carcinoma? Rudhart SA; Schultz JD; Gehrt F; Pavel FL; Birk R; Hoch M; Stuck BA; Hoch S Eur Arch Otorhinolaryngol; 2019 Dec; 276(12):3467-3475. PubMed ID: 31482332 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21-1) for bladder cancer: a systematic review and meta-analysis. Huang YL; Chen J; Yan W; Zang D; Qin Q; Deng AM Tumour Biol; 2015 May; 36(5):3137-45. PubMed ID: 25854170 [TBL] [Abstract][Full Text] [Related]
5. Cytokeratin-19 fragment in the diagnosis of bladder carcinoma. Guo XG; Long JJ Tumour Biol; 2016 Oct; 37(10):14329-14330. PubMed ID: 27448817 [TBL] [Abstract][Full Text] [Related]
6. Study of cyfra 21-1, a tumor marker, in head and neck squamous cell carcinoma. Céruse P; Rabilloud M; Charrié A; Dubreuil C; Disant F Ann Otol Rhinol Laryngol; 2005 Oct; 114(10):768-76. PubMed ID: 16285267 [TBL] [Abstract][Full Text] [Related]
7. Early diagnosis of radiotherapy failure for patients with head and neck cancer: the role of biochemical markers. Mrochem-Kwarciak J; Rutkowski T; Wygoda A; Deja R; Hajduk A; Składowski K Tumori; 2018 Aug; 104(4):273-279. PubMed ID: 28604997 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis. Liu L; Xie W; Xue P; Wei Z; Liang X; Chen N PLoS One; 2019; 14(5):e0216561. PubMed ID: 31071161 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Cyfra 21-1 and SCC assays in head and neck tumours. Banal A; Hacene K; Berthelot-Ruff E; Mahé E; Fontana X; Pichon MF Tumour Biol; 2001; 22(1):27-35. PubMed ID: 11054024 [TBL] [Abstract][Full Text] [Related]
10. [Investigation of the usefulness of CYFRA 21-1 as a tumor marker in squamous cell carcinomas of the head and neck]. Sano K; Kataoka S; Katoh T; Kawauchi H; Morikawa S Nihon Jibiinkoka Gakkai Kaiho; 1997 Jul; 100(7):790-7. PubMed ID: 9277101 [TBL] [Abstract][Full Text] [Related]
11. Squamous cell carcinoma antigen as a prognostic marker and its correlation with clinicopathological features in head and neck squamous cell carcinoma: Systematic review and meta-analysis. Travassos DC; Fernandes D; Massucato EMS; Navarro CM; Bufalino A J Oral Pathol Med; 2018 Jan; 47(1):3-10. PubMed ID: 28600896 [TBL] [Abstract][Full Text] [Related]
12. Elevated serum CYFRA 21-1 level as a diagnostic marker for thymic carcinoma. Shiiya H; Ujiie H; Hida Y; Kato T; Kaga K; Wakasa S; Kikuchi E; Shinagawa N; Okada K; Ito YM; Matsuno Y Thorac Cancer; 2021 Nov; 12(21):2933-2942. PubMed ID: 34581013 [TBL] [Abstract][Full Text] [Related]
13. The accuracy of Fiber-Optic Raman Spectroscopy in the detection and diagnosis of head and neck neoplasm Chen W; Chen Y; Wu C; Zhang X; Huang X PeerJ; 2023; 11():e16536. PubMed ID: 38099303 [TBL] [Abstract][Full Text] [Related]
14. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients. Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719 [TBL] [Abstract][Full Text] [Related]
15. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. Deng YF; Chen P; Lin YZ; Le JZ; Wu XL; Yu MQ; Zhuang PY; Gao MH J Laryngol Otol; 2003 Mar; 117(3):190-4. PubMed ID: 12648374 [TBL] [Abstract][Full Text] [Related]
16. Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Doweck I; Barak M; Greenberg E; Uri N; Kellner J; Lurie M; Gruener N Arch Otolaryngol Head Neck Surg; 1995 Feb; 121(2):177-81. PubMed ID: 7530966 [TBL] [Abstract][Full Text] [Related]
17. Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck. Kuropkat C; Lippert BM; Werner JA Oncology; 2002; 63(3):280-5. PubMed ID: 12381908 [TBL] [Abstract][Full Text] [Related]
18. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis. Cui C; Sun X; Zhang J; Han D; Gu J J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270 [TBL] [Abstract][Full Text] [Related]
19. [Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck]. González Sánchez E; López-Ríos Velasco J; Calvo Boizas E; García-Talavera Fernández JR; Martín Ro-dríguez M; Muñoz Herrera A; Del Cañizo Alvarez A Acta Otorrinolaringol Esp; 1999 Mar; 50(2):85-9. PubMed ID: 10217679 [TBL] [Abstract][Full Text] [Related]
20. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Wollenberg B; Jan V; Schmit UM; Hofmann K; Stieber P; Fateh-Moghadam A Anticancer Res; 1996; 16(5B):3117-24. PubMed ID: 8920778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]